Phase I clinical evaluation of diaziquone in childhood cancer.

  title={Phase I clinical evaluation of diaziquone in childhood cancer.},
  author={Lawrence J. Ettinger and Stuart E. Siegel and Jean Bello Belasco and Audrey E. Evans and Kathleen S. Ruccione and D C Jamin and T M Rohrbaugh and Gussie R Higgins},
  journal={Cancer treatment reports},
  volume={69 3},
Diaziquone (AZQ), a new lipid-soluble antitumor agent, was given by 15-30-minute infusion on a daily X 5 schedule to 47 children with refractory solid tumors and leukemia. The starting daily dose of 6 mg/m2 was escalated to 10 and 35 mg/m2 in patients with solid tumors and leukemia, respectively. In patients with solid tumors, myelosuppression was dose-limiting at a daily dose of 10 mg/m2. In patients with leukemia, prolonged pancytopenia and bone marrow hypoplasia were observed at daily doses… CONTINUE READING